Acepodia, Inc. (TPEX: 6976)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
17.80
-0.30 (-1.66%)
Nov 15, 2024, 2:59 PM CST
-43.40%
Market Cap 10.28B
Revenue (ttm) 16.90M
Net Income (ttm) -379.78M
Shares Out 569.64M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 597,897
Open 18.10
Previous Close 18.10
Day's Range 17.10 - 18.20
52-Week Range 17.00 - 36.40
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 12, 2024

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address gaps in cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies. It develops ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in preclinical study; ACE1708; and ACE1702 targeting HER2 that is in phase 1 clinical trial. Acepodia Inc.... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Sonny Hsiao
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 6976
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.